# Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

*PRI Rank #3 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-3*

| Field | Value |
| --- | --- |
| Rank | #3 |
| 18m citations | 115 |
| Journal | Annals of Oncology |
| Year | 2024 |
| DOI | 10.1016/j.annonc.2024.04.013 |
| Corresponding authors | M.P. Goetz |
| Institution | Mayo Clinic, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1016/j.annonc.2024.04.013](https://doi.org/10.1016/j.annonc.2024.04.013)

## Topics

abemaciclib · nonsteroidal aromatase inhibitor · HR+ HER2− advanced breast cancer · MONARCH 3 · overall survival · progression-free survival · anastrozole · letrozole · postmenopausal women · initial therapy · visceral disease · chemotherapy-free survival · CDK4/6 inhibitor · endocrine therapy · Phase 3 trial · fulvestrant

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```